ADMA BIOLOGICS INC
NASDAQ: ADMA (ADMA Biologics Inc)
Last update: 6 hours ago17.52
0.02 (0.11%)
| Previous Close | 17.50 |
| Open | 17.53 |
| Volume | 1,510,797 |
| Avg. Volume (3M) | 2,828,121 |
| Market Cap | 4,180,810,240 |
| Price / Earnings (TTM) | 20.37 |
| Price / Earnings (Forward) | 28.99 |
| Price / Sales | 8.77 |
| Price / Book | 9.60 |
| 52 Weeks Range |
| Profit Margin | 45.01% |
| Operating Margin (TTM) | 30.38% |
| Diluted EPS (TTM) | 0.840 |
| Quarterly Revenue Growth (YOY) | 40.20% |
| Quarterly Earnings Growth (YOY) | 51.10% |
| Total Debt/Equity (MRQ) | 21.96% |
| Current Ratio (MRQ) | 6.58 |
| Operating Cash Flow (TTM) | 101.22 M |
| Levered Free Cash Flow (TTM) | 52.62 M |
| Return on Assets (TTM) | 22.06% |
| Return on Equity (TTM) | 78.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ADMA Biologics Inc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.58% |
| % Held by Institutions | 89.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Thrivent Financial For Lutherans | 30 Sep 2025 | 4,141,840 |
| Capital Research Global Investors | 30 Sep 2025 | 3,253,913 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update |
| 05 Jan 2026 | Announcement | ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026 |
| 05 Nov 2025 | Announcement | ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |